[Translation] A randomized, open-label, two-sequence, two-period, double-crossover bioequivalence study of a single oral dose of meloxicam tablets in Chinese healthy volunteers after fasting or feeding
研究空腹及餐后单次口服美洛昔康片受试制剂(普利洛®,7.5 mg/片,江苏飞马药业有限公司)与美洛昔康片参比制剂(MOBEC ®,7.5 mg/片,Boehringer Ingelheim Pharma GmbH& Co.KG)后美洛昔康在中国健康志愿者体内的PK(Pharmacokinetics,药代动力学)行为,评价空腹及餐后口服两种制剂的生物等效性。
次要目的:
评价中国健康志愿者单次口服美洛昔康片受试制剂和参比制剂后的安全性。
[Translation] To study the PK (Pharmacokinetics) behavior of meloxicam in healthy Chinese volunteers after a single oral administration of the test formulation of meloxicam tablets (Prilo®, 7.5 mg/tablet, Jiangsu Pegasus Pharmaceutical Co., Ltd.) and the reference formulation of meloxicam tablets (MOBEC®, 7.5 mg/tablet, Boehringer Ingelheim Pharma GmbH & Co.KG) on an empty stomach and after a meal, and to evaluate the bioequivalence of the two formulations after an empty stomach and after a meal.
Secondary objective:
To evaluate the safety of the test formulation and reference formulation of meloxicam tablets in healthy Chinese volunteers after a single oral administration.